Effect of CYP2C192 and 17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications

The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications. A total of 730 patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 2013-04, Vol.111 (7), p.985-990
Hauptverfasser:	Grosdidier, Charlotte, MD, Quilici, Jacques, MD, Loosveld, Marie, MD, Camoin, Laurence, PhD, Moro, Pierre Julien, MD, Saut, Noémie, PhD, Gaborit, Bénédicte, MD, Pankert, Mathieu, MD, Cohen, William, MD, Lambert, Marc, MD, Beguin, Shirley, PhD, Morange, Pierre Emmanuel, MD, PhD, Bonnet, Jean-Louis, MD, Alessi, Marie-Christine, MD, PhD, Cuisset, Thomas, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - genetics Acute Coronary Syndrome - metabolism Acute coronary syndromes Alleles Aryl Hydrocarbon Hydroxylases - genetics Blood platelets Blood Platelets - drug effects Cardiovascular Cardiovascular disease Cell Adhesion Molecules Cytochrome P-450 CYP2C19 Deoxyribonucleic acid DNA Drug dosages Female Genetic Variation Genotype Heart attacks Hemorrhage - genetics Humans Male Microfilament Proteins Middle Aged Mortality Myocardial Infarction - drug therapy Myocardial Infarction - genetics Myocardial Infarction - metabolism Phosphoproteins Piperazines - administration & dosage Piperazines - therapeutic use Polymerase Chain Reaction Prasugrel Hydrochloride Prospective Studies Purinergic P2Y Receptor Antagonists - administration & dosage Purinergic P2Y Receptor Antagonists - therapeutic use Risk Factors Thiophenes - administration & dosage Thiophenes - therapeutic use Thrombosis Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Treatment Outcome Variables
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) 2 and 17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications. A total of 730 patients were included (517 patients treated with clopidogrel 150 mg/day and 213 discharged with prasugrel 10 mg). Platelet reactivity was assessed at 1 month with the platelet reactivity index vasodilator-stimulated phosphoprotein (PRI VASP). High on-treatment platelet reactivity was defined as PRI VASP >50% and low on-treatment platelet reactivity (LTPR) as PRI VASP
ISSN:	0002-9149 1879-1913
DOI:	10.1016/j.amjcard.2012.12.013